Nurses Spot Gaps in Application of Clinical Guidelines for Anemia

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

WASHINGTON, DC-Recombinant human erythropoietin is accepted treatment for chemotherapy-related anemia, but a panel of four oncology nurses convened to review an evidence-based clinical practice guideline for anemia concluded that guidelines are not being consistently followed. The panel’s findings were presented by Denise Oseguera, RN, of University of California, Los Angeles, and Susan Ross, MD, of MetaWorks Inc., Medford, Massachusetts.

WASHINGTON, DC—Recombinant human erythropoietin is accepted treatment for chemotherapy-related anemia, but a panel of four oncology nurses convened to review an evidence-based clinical practice guideline for anemia concluded that guidelines are not being consistently followed. The panel’s findings were presented by Denise Oseguera, RN, of University of California, Los Angeles, and Susan Ross, MD, of MetaWorks Inc., Medford, Massachusetts.

The panel identified major barriers to and benefits of implementing guidelines and pointed to clinic nurses as key to improving management of anemia in cancer patients. "Oncology nurses are often the first caregivers with the opportunity to assess anemia in cancer outpatients. The success or failure of implementation of any ‘global’ clinical practice guideline hinges on removing local barriers and emphasizing local benefits," Ms. Oseguera said. "In oncology clinic settings, nurses are the key implementers—knowledgeable about practice-specific circumstances and equipped to champion process improvements."

Treatment Triggers Vary

The panel of four oncology nurses represented disparate practice settings in Los Angeles, Salt Lake City, St. Louis, and Minneapolis. "Outpatient oncology practice is heavily dependent upon nurses as both patient advocates and front-line care providers. Success of guidelines in this setting depends on identifying and addressing issues unique to nurses," Ms. Oseguera said.

The guideline for the treatment of chemotherapy-related anemia focused on the use of erythropoietin and was developed by a multidisciplinary panel following a systematic review of the literature through August 2000. The study to review the guideline was funded by Amgen.

The panel found that triggers for anemia treatment varied greatly at the different geographical locations (see Table 1). Panel members said that implementing the anemia guideline would improve care, reduce error, reduce direct and indirect transfusion-associated costs, improve adherence to chemotherapy schedules, and improve workflow.

Implementation Barriers

The nurses identified variable reimbursement rules, especially regarding whether treatment was given in the office or in the hospital, as a major barrier to implementation of the anemia practice guideline. Other barriers included excessive time required by nurses to pre-certify payment for erythropoietin and patient inconvenience (especially with regard to frequency of injections).

The nurses also cited "variable physician attitudes toward recognizing and treating symptoms of anemia and toward ‘soft’ measures of efficacy such as cognitive function and quality of life" as barriers, Ms. Oseguera reported. An equally important problem was institutional failure to assess all costs associated with anemia when considering interventions.

"The knowledgeable support of nurses, in addition to scientific advances such as the development of a new generation of erythropoiesis stimulating proteins to overcome dosing inconvenience barriers, may facilitate guideline acceptance," Ms. Oseguera concluded.

Related Videos
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Related Content